Your browser doesn't support javascript.
loading
Clinical Experience of External Application of Clearing Heat and Removing Dampness in Relieving Grade 2 to 3 Rash Caused by Programed Cell Death Protein 1 (PD-1)/Programed Cell Death Ligand 1 (PD-L1) Inhibitors: A Single-Center Retrospective Study.
Chen, Shu-Yi; Zhao, Fang-Min; Yu, Rui; Sun, Lin; Yin, Yu-Dan; Zhang, Gao-Chen-Xi; Yang, Jia-Yao; Shu, Qi-Jin.
Afiliación
  • Chen SY; Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
  • Zhao FM; The First Clinical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Yu R; The First Clinical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Sun L; The First Clinical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Yin YD; The First Clinical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Zhang GC; Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
  • Yang JY; The First Clinical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Shu QJ; Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
Integr Cancer Ther ; 23: 15347354231226108, 2024.
Article en En | MEDLINE | ID: mdl-38240227
ABSTRACT

OBJECTIVE:

In China, grade 2 to 3 immune-related rash will probably lead to the interruption of immunotherapy. Corticosteroid (CS) is the main treatment, but not always effective. The external application of clearing heat and removing dampness, which is represented by Qing-Re-Li-Shi Formula (QRLSF), has been used in our hospital to treat immune-related cutaneous adverse events (ircAEs) for the last 5 years. The purpose of this study was to discuss its efficacy and safety in the treatment of grade 2 to 3 rash.

METHODS:

A retrospective study of patients with grade 2 to 3 immune-related rash in our hospital from December 2019 to December 2022 was conducted. These patients received QRLSF treatment. Clinical characteristics, treatment outcome, and health-related quality of life (HrQoL) were analyzed.

RESULTS:

Thirty patients with grade 2 to 3 rash (median onset time 64.5 days) were included. The skin lesions of 24 cases (80%) returned to grade 1 with a median time of 8 days. The accompanying symptoms were also improved with median time of 3 to 4 days. The addition of antihistamine (AH) drug didn't increase the efficacy of QRLSF (AH + QRLSF 75.00% vs QRLSF 83.33%, P = .66). No significant difference was observed in the efficacy of QRLSF treatment regardless of whether patients had previously received CS therapy (untreated population 88.24% vs treated population 69.23%, P = .36). During 1-month follow-up, 2 cases (8.33%) underwent relapses. In terms of HrQoL, QRLSF treatment could significantly reduce the median scores of all domains of Skindex-16, including symptoms (39.58 vs 8.33, P < .0001), emotions (58.33 vs 15.48, P < .0001), functioning (46.67 vs 13.33, P < .0001) and composite (52.60 vs 14.06, P < .0001).

CONCLUSION:

External application of clearing heat and removing dampness was proven to be an effective and safe treatment for such patients. In the future, high-quality trials are required to determine its clinical application in the field of ircAEs.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Exantema / Antígeno B7-H1 / Receptor de Muerte Celular Programada 1 Tipo de estudio: Observational_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Integr Cancer Ther Asunto de la revista: NEOPLASIAS / TERAPEUTICA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Exantema / Antígeno B7-H1 / Receptor de Muerte Celular Programada 1 Tipo de estudio: Observational_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Integr Cancer Ther Asunto de la revista: NEOPLASIAS / TERAPEUTICA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos